Figure 7. Aberrant BMI1 amplification contributed to BMI1 overexpression and chemoresistance in bladder cancer. (A, B) Analysis of BMI1 copy number variant (CNV) in bladder cancer patients resistant to chemotherapy (A) and that sensitive to chemotherapy (B) in TCGA-BLCA data sets. (C, D) BMI1 gene CNV and corresponding mRNA expression in bladder cancer patients resistant chemotherapy (C) vs. that sensitive to chemotherapy (D) in TCGA-BLCA data sets (P = 0.0254). (E) BMI1 gene CNV and corresponding mRNA expression in a TCGA bladder cancer data set (P < 0.001). (F) Kaplan-Meier analysis of overall survival for patients with amplified or non-amplified BMI1 expression (P = 0.0383). *P < 0.05. **P < 0.01. ***P < 0.001. CNV: copy number variation; TCGA: The Cancer Genome Atlas; BLCA: Bladder Urothelial Carcinoma.